科拓生物(300858) - 科拓生物调研活动信息

Group 1: Company Overview and Market Position - The company has been focusing on the research and development of probiotics, particularly in the area of Helicobacter pylori, which has gained significant market attention recently [2][3] - Since its establishment, the company has relied on its proprietary strain resources and has conducted over 50 clinical trials in collaboration with top-tier hospitals, with 29 trials completed [3] - The company aims to achieve technological breakthroughs and deliver products that benefit consumers and society [3] Group 2: Product Development and Clinical Trials - The company has identified several key probiotic strains, including Lactobacillus Zhang and Bifidobacterium V9, and has validated their beneficial functions through large-scale clinical trials [3] - The company has expanded into the probiotic pharmaceutical sector since 2019, elevating its research efforts [3] - The focus on Helicobacter pylori will continue, with ongoing product design and research efforts [3] Group 3: Investor Insights and Market Growth - The company believes it is on par with international probiotic companies in terms of research and development, despite starting later [3] - The domestic probiotic market is experiencing rapid growth, with significant market share still held by multinational corporations [3] - As the only publicly listed probiotic company in China, the company is confident in the future growth of its probiotic product segment [3]